Ezetimibe BE [Regulatives / Guidelines]

posted by Mutasim – Jordan, 2019-09-23 14:40 (572 d 23:03 ago) – Posting: # 20641
Views: 3,761

Dear Members,
Would you please advice on interpretation of the requirements for Ezetimibe BE according to the last guidance by EMA, in particular the statement
"Main pharmacokinetic variables: AUC0-72h, Cmax
Background/justification: On total (parent + glucuronide metabolite together)
Does it mean measuring each one alone? or the total as in FDA guidance? and accordingly will the CI be for each one alone or both unconjugated and total or only total?


Edit: Guideline linked. [Helmut]

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 13 (0 registered, 13 guests [including 4 identified bots]).
Forum time: Sunday 13:44 CEST (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5